Exscientia (EXAI)
NASDAQ: EXAI
· Real-Time Price · USD
4.84
null (null%)
At close: Nov 19, 2024, 9:00 PM
Company Description
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs.
The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection.
In addition, the company focuses on small molecule drug candidates.
Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment.
The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.
Exscientia
| Country | GB |
| IPO Date | Oct 1, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 483 |
| CEO | Dr. David Hallett Ph.D. |
Contact Details
Address: The SchrOedinger Building Oxford, GB | |
| Website | https://www.exscientia.ai |
Stock Details
| Ticker Symbol | EXAI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001865408 |
| CUSIP Number | 30223G102 |
| ISIN Number | US30223G1022 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. David Hallett Ph.D. | Chief Scientific Officer, Interim Chief Executive Officer, Principal Executive Officer & Executive Director |
| Ben R. Taylor | Chief Financial Officer, Chief Strategy Officer & Executive Director |
| Caroline Rowland | Chief People Officer |
| Dr. John P. Overington Ph.D. | Chief Technology Officer |
| Dan Ireland | Executive Vice President of Legal & Company Secretary |
| Dr. Marie-Louise Helena Fjallskog M.D., Ph.D. | Interim Chief Medical Officer & Clinical Development Lead |
| Nikolaus Krall | Executive Vice President of Precision Medicine |
| Parker Moss | Executive Vice President of Corporate Development |
| Richard Law | Chief Business Officer |
| Sara Sherman | Vice President of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 02, 2024 | 15-12G | Filing |
| Nov 22, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 22, 2024 | SC 13D/A | [Amend] Filing |
| Nov 20, 2024 | S-8 POS | Filing |
| Nov 20, 2024 | S-8 POS | Filing |
| Nov 20, 2024 | 6-K | Filing |
| Nov 20, 2024 | 25-NSE | Filing |
| Nov 13, 2024 | 6-K | Filing |
| Nov 12, 2024 | 6-K | Filing |
| Nov 08, 2024 | 6-K | Filing |